This headline may be true (check our YouTube version for proof!), but the bromance certainly hit a bumpy patch when it came to discussing Keynote 564 on GU Cast today!
We congratulate Dr Toni Chouieri (Medical Oncologist and Director of the Lank Center for GU Oncology, Dana Farber Cancer Institute), and colleagues for the publication of Keynote 564 in NEJM recently, and to Toni for his plenary at ASCO this year. And we welcome Dr Alex Kutikov, Urologist and Chief of Urologic Oncology at Fox Chase Cancer Centre, and an old mate of Toni's, and studio guest Associate Professor Ben Tran, Medical Oncologist and GU Trials Director at Peter MacCallum Cancer Centre.
Keynote 364 is a randomised trial of adjuvant pembrolizamab in patients following surgery for kidney cancer, and made headlines when Dr Chouieri presented the findings in an ASCO Plenary, reporting a significant prolongation of disease-free survival for patients receiving pembro. The paper followed recently in NEJM.
So does this mean pembro for all? Do we need to wait for overall survival? What about over-treatment? Can't patients just have combination I/O instead on relapse? Etc etc!!!
Your hosts as ever, Declan Murphy and Renu Eapen.

Links:
GU Cast on YouTube
Keynote 564 NEJM paper
Dr Chouieri Twitter
Alex Kutikov Twitter
Ben Tran Twitter